Sentrex Health Solutions announced the acquisition of PerCuro Clinical Research, a full-service specialty pharmacy and healthcare services provider based in Victoria, Canada.
PerCuro Clinical Research provides infusion services, clinical research and advanced nursing care. The company treats patients across several therapeutic areas, including inflammatory bowel disease, liver disease, neurology, dermatology and rare diseases. Established in 2003, PerCuro partners with healthcare providers on Vancouver Island, bringing healthcare services closer to physicians and patients.
Sentrex Health Solutions Inc. is a Canadian healthcare company based in Markham, Ontario. The company provides patient-focused specialty pharmacy and patient support program services across a range of medical fields including ophthalmology, hepatology, gastroenterology, neurology, oncology and rare diseases.
Commenting on the acquisition, Leeanna Bulinckx, Founder & CEO of PerCuro, said: “Joining forces with Sentrex represents a pivotal moment for us. We’re excited to extend our tried-and-true PerCuro model beyond Vancouver Island to serve patients, and Sentrex, with its similar focus on exceptional patient care, will make this possible.”
Both organizations are dedicated to delivering seamless care through the transition, while ensuring continued high-quality care for all patients and stakeholders involved. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the fifth specialty pharmacy acquisition of the year. There were 15 specialty pharmacy transactions announced during 2023.
